[8-K] Medpace Holdings, Inc. Reports Material Event

Rhea-AI Filing Summary

Schedule 13G filing – Blueprint Medicines Corp. (BPMC)

Hedge-fund complex Davidson Kempner and affiliates (M.H. Davidson & Co., Davidson Kempner Arbitrage, Equities & Relative Value LP, Davidson Kempner Capital Management LP and managing member Anthony A. Yoseloff) disclose beneficial ownership of 0 shares and 0% of BPMC common stock as of the 14 Jul 2025 reportable event. Rows 5-8 of each cover page show no sole or shared voting or dispositive power. Item 5 confirms they now hold “5 percent or less” of the class. Historically, the group previously exceeded the 5 % threshold, triggering the original 13G; this amendment reflects a complete exit or reduction below the reporting threshold.

All reporting persons list the same business address (9 W 57th St., New York) and certify the shares were not acquired to influence control. The filing therefore signals that a significant institutional holder has fully unwound its position in Blueprint Medicines.

Positive

• None.

Negative

• Large institutional holder has reduced its position in BPMC to 0 %, eliminating prior >5 % stake

Insights

Portfolio Manager

TL;DR: Davidson Kempner reports 0% stake in BPMC, indicating full exit by a once-large holder.

The filing shows all affiliated entities now control no shares. Hedge-fund departures can signal profit-taking or diminished conviction. While not dilutive, it removes a potential “sticky” shareholder that might have supported the stock during volatility. Absence of voting power also reduces activist risk from this group. Investors should monitor trading volumes around 14 Jul 2025 to gauge if the exit pressured share price.

Corporate Governance Specialist

TL;DR: Governance impact minimal; disclosure formalises sub-5 % status.

Because the group certifies no intent to influence control, governance ramifications are limited. The exit diminishes concentration among top holders, potentially broadening the float. Management loses a knowledgeable biotech investor but gains marginally more flexibility in strategic actions without needing to consult this fund.

FALSE000166839700016683972025-07-172025-07-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________________________________________________

FORM 8-K

______________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 17, 2025

______________________________________________________

Medpace Holdings, Inc.

(Exact name of Registrant as Specified in Its Charter)

______________________________________________________

Delaware			001-37856			32-0434904
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)
5375 Medpace Way
Cincinnati, Ohio						45227
(Address of Principal Executive Offices)						(Zip Code)

Registrant’s Telephone Number, Including Area Code: 513 579-9911

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

______________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock $0.01 par value

MEDP

NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 1.01 Entry into a Material Definitive Agreement.

On July 17, 2025, Medpace Holdings, Inc., a Delaware corporation (the "Company"), through its wholly owned subsidiaries, Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No.9 to Loan Documents (“Amendment No. 9”) with PNC Bank, National Association in connection with the Company’s unsecured credit facility (the “Loan Documents”). Amendment No. 9 changes the aggregate principal amount that may be borrowed under the facility’s line of credit to up to $10 million.

The foregoing description of Amendment No. 9 is qualified in its entirety by reference to Amendment No. 9. A copy of Amendment No. 9 is filed herewith as Exhibit 10.1 and incorporated herein by reference.

Item 2.02 Results of Operations and Financial Condition.

On July 21, 2025, the Company issued a press release announcing its financial results for the three and six months ended June 30, 2025. The full text of the press release was posted on the Company’s internet website and is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, Item 2.02, including the press release attached as Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
10.1						Amendment No. 9 dated July 17, 2025 to Loan Documents
99.1						Press release dated July 21, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

									MEDPACE HOLDINGS, INC.
Date:			July 21, 2025			By:			/s/ Kevin M. Brady
									Kevin M. Brady, Chief Financial Officer

FAQ

Why did Davidson Kempner file a Schedule 13G for Blueprint Medicines (BPMC)?

Because its aggregate holdings dropped to 5 % or less, requiring an update under SEC Rule 13d-1.

How many Blueprint Medicines shares does Davidson Kempner currently own?

The filing lists 0 shares with no voting or dispositive power.

What percentage of BPMC’s outstanding shares does this represent?

The reported ownership is 0 % of the common stock class.

Does the filing indicate an attempt to influence Blueprint Medicines’ control?

No. The certification states the securities were not acquired to change or influence control.

When was the reportable event triggering this filing?

The event date is 14 July 2025, with signatures dated 21 July 2025.